Financial PerformanceDHR aims for high single-digit long-term growth in its Diagnostics segment, with innovation, menu expansion, and market execution as key drivers.
Growth OpportunitiesDHR plans over 20 new assay launches in the next 5 years, targeting major opportunities in non-respiratory markets such as oncology, hospital-acquired infections, and women's health.
Strategic PositioningDHR's repositioning strategy to emphasize growth and innovation at a platform level is expected to unlock new diagnostic areas and optimize the existing portfolio's potential.